| Curtis P Ross, DO | |
|
55 Broadway Ste 2, Bangor, ME 04401-5201 | |
| (207) 947-0469 | |
| (207) 947-5368 |
| Full Name | Curtis P Ross |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 15 Years |
| Location | 55 Broadway Ste 2, Bangor, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063640555 | NPI | - | NPPES |
| 102899831 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | Q1012 (Texas) | Secondary |
| 208800000X | Urology | 14109 (California) | Secondary |
| 208800000X | Urology | DO2978 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Hospital | Bangor, ME | Hospital |
| Eastern Maine Medical Center | Bangor, ME | Hospital |
| Mayo Regional Hospital | Dover foxcroft, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eastern Maine Medical Center | 2062315161 | 577 |
| St Joseph Hospital | 6406766336 | 155 |
News Archive
Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.
A world-leading taskforce led by The University of Manchester has begun work to create a new test to help medics work out which treatment plan is most likely to improve the disabling skin condition psoriasis, based on a patient's individual biological make-up.
A group of New Zealand health policy researchers from the University of Otago's Dunedin and Christchurch campuses has called on the leading medical journal BMJ to be much more even handed in scrutinizing the transparency of what it publishes.
Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
Media can register now for Europe's premier cancer congress: The 2011 European Multidisciplinary Cancer Congress in Stockholm, 23-27 September 2011
› Verified 4 days ago
| Entity Name | Eastern Maine Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790789147 PECOS PAC ID: 2062315161 Enrollment ID: O20040128000088 |
News Archive
Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.
A world-leading taskforce led by The University of Manchester has begun work to create a new test to help medics work out which treatment plan is most likely to improve the disabling skin condition psoriasis, based on a patient's individual biological make-up.
A group of New Zealand health policy researchers from the University of Otago's Dunedin and Christchurch campuses has called on the leading medical journal BMJ to be much more even handed in scrutinizing the transparency of what it publishes.
Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
Media can register now for Europe's premier cancer congress: The 2011 European Multidisciplinary Cancer Congress in Stockholm, 23-27 September 2011
› Verified 4 days ago
| Entity Name | St Joseph Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154321545 PECOS PAC ID: 6406766336 Enrollment ID: O20040604000895 |
News Archive
Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.
A world-leading taskforce led by The University of Manchester has begun work to create a new test to help medics work out which treatment plan is most likely to improve the disabling skin condition psoriasis, based on a patient's individual biological make-up.
A group of New Zealand health policy researchers from the University of Otago's Dunedin and Christchurch campuses has called on the leading medical journal BMJ to be much more even handed in scrutinizing the transparency of what it publishes.
Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
Media can register now for Europe's premier cancer congress: The 2011 European Multidisciplinary Cancer Congress in Stockholm, 23-27 September 2011
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Curtis P Ross, DO 43 Whiting Hill Rd Ste 300, Brewer, ME 04412-1006 Ph: () - | Curtis P Ross, DO 55 Broadway Ste 2, Bangor, ME 04401-5201 Ph: (207) 947-0469 |
News Archive
Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.
A world-leading taskforce led by The University of Manchester has begun work to create a new test to help medics work out which treatment plan is most likely to improve the disabling skin condition psoriasis, based on a patient's individual biological make-up.
A group of New Zealand health policy researchers from the University of Otago's Dunedin and Christchurch campuses has called on the leading medical journal BMJ to be much more even handed in scrutinizing the transparency of what it publishes.
Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
Media can register now for Europe's premier cancer congress: The 2011 European Multidisciplinary Cancer Congress in Stockholm, 23-27 September 2011
› Verified 4 days ago
Dr. Ali Khavari, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 55 Broadway, Suite 2, Bangor, ME 04401 Phone: 207-973-8881 Fax: 207-947-5368 | |
Brendan Wallace, MD Urology Medicare: Medicare Enrolled Practice Location: 55 Broadway, Bangor, ME 04401 Phone: 207-947-0469 | |
Dr. Jonas Gricius, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 55 Broadway Fl 2, Bangor, ME 04401 Phone: 207-947-0469 Fax: 207-947-5368 | |
Catlin Flynn, Urology Medicare: Accepting Medicare Assignments Practice Location: 55 Broadway Ste 2, Bangor, ME 04401 Phone: 207-947-0469 |